UniProtKB/SwissProt variant VAR

Variant information

Variant position:

638

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

Polymorphism

The variants are classified into three categories: Disease, Polymorphism and Unclassified.

Disease: Variants implicated in disease according to literature reports.
Polymorphism: Variants not reported to be implicated in disease.
Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:

From Methionine (M) to Valine (V) at position 638 (M638V, p.Met638Val).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic.

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

1

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Other resources:

Links to websites of interest for the variant.

Variant rs1874792 [ dbSNP | Ensembl ]

Sequence information

Variant position:

638

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

4391

The length of the canonical sequence.

Location on the sequence:

VRYELARGMLEPVQRPDVVL M GAGYRLLSRGHTPTQPGALN

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VRYELARGMLEPVQRPDVVLMGAGYRLLSRGHTPTQPGALN

Mouse                         VRYELARGMLEPVQKPDVILVGAGYRLHSRGHTPTHPGTLN

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	22 – 4391	Basement membrane-specific heparan sulfate proteoglycan core protein
Domain	538 – 730	Laminin IV type A 1

Literature citations

Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor.
Murdoch A.D.; Dodge G.R.; Cohen I.; Tuan R.S.; Iozzo R.V.;
J. Biol. Chem. 267:8544-8557(1992)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS VAL-638; SER-765 AND VAL-1503;

Human basement membrane heparan sulfate proteoglycan core protein: a 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor.
Kallunki P.; Tryggvason K.;
J. Cell Biol. 116:559-571(1992)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS VAL-638; SER-765; VAL-1503; HIS-2980; GLY-2995; THR-3168 AND GLN-3632;

Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia).
Nicole S.; Davoine C.-S.; Topaloglu H.; Cattolico L.; Barral D.; Beighton P.; Ben-Hamida C.; Hammouda H.; Cruaud C.; White P.S.; Samson D.; Urtizberea J.A.; Lehmann-Horn F.; Weissenbach J.; Hentati F.; Fontaine B.;
Nat. Genet. 26:480-483(2000)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-4391; VARIANTS VAL-638 AND SJS1 TYR-1532; VARIANTS SER-765 AND VAL-1503;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P98160: Variant p.Met638Val